IL-17 inhibitors may (a) increase sensitivity to chemotherapy and radiation [32], (b) suppress metastasis [32], (c) improve the efficacy of immunotherapy, especially for tumors that are resistant to ICI [30], (d) or, in combination with ICI, may reduce the tumor burden in lung cancer [31,32]. This evidence concerns the gene IL17A and lung carcinoma.